<DOC>
	<DOCNO>NCT00951574</DOCNO>
	<brief_summary>In phase III , multicenter study , 1200 patient lung , breast , gastrointestinal ( stomach , colon-rectum , pancreas ) , ovarian head neck cancer undergo chemotherapy randomly assign ( begin cytotoxic therapy ) 2:1 ratio double-blind condition treatment subcutaneous low molecular weight heparin ( nadroparin calcium , one injection/day ) placebo overall duration chemotherapy maximum 4 month ( +/- 10 day ) .</brief_summary>
	<brief_title>Prevention Venous Arterial Thromboembolism , Cancer Patients Undergoing Chemotherapy , With Low Molecular Weight Heparin ( Nadroparin Calcium )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>INCLUSION CRITERIA : sex ; age &gt; 18 year ; suffer different type malignancy ( lung , breast , gastric , colon rectum , pancreatic , ovarian , head neck cancer ) undergo systemic chemotherapy , sign Informed Consent prior initiation study procedure . EXCLUSION CRITERIA : adjuvant neoadjuvant chemotherapy ; objectively confirm venous arterial thromboembolism last three month ; antithrombotic treatment indication ; life expectancy le 3 month ; Performance Status &gt; 2 ( ECOG ) ; active bleeding bleeding last four week require hospitalization , transfusion surgical intervention ; bleed diathesis ( prothrombin time &lt; 70 % activate partial thromboplastin time ratio &gt; 1.3 ) , platelet count &lt; 50x10^9/L ; cerebrovascular hemorrhage last six month ; know active gastric duodenal ulcer ; know cerebral metastasis ; cerebral aneurysm ; IIIIV grade diabetic retinopathy ; severe uncontrolled hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg ) ; chronic atrial fibrillation ; acute endocarditis ; acute pancreatitis ; know hypersensitivity unfractionated heparin LMWH ; previous occurrence heparininduced thrombocytopenia ; renal impairment ( dependent dialysis creatinine high 2.5mg % ) ; liver insufficiency ( alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase level &gt; 3 time upper limit normal range and/or total bilirubin &gt; 3.0 mg/ml ) ; pregnancy childbearing potential without adequate contraception ; treatment investigational drug patient inclusion clinical trial ; patient unable fulfill study requirement term visits/compliance treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>thromboembolism</keyword>
	<keyword>cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>low-molecular-weight-heparin</keyword>
	<keyword>nadroparin</keyword>
</DOC>